Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective

Publication date

2018-06-08T07:50:15Z

2018-11-30T06:10:18Z

2017-11

2018-06-08T07:50:15Z

Abstract

The objective of this study was to assess the cost-effectiveness of insulin degludec versus insulin glargine, from the Spanish NHS in three groups of patients. Methods: A short-term cost utility model was developed to estimate effectiveness results in terms of the total number of hypoglycaemic events and their disutility impact throughout the year on the initial level of quality of life for patients in each treatment .

Document Type

Article


Accepted version

Language

English

Publisher

Informa Healthcare

Related items

Versió postprint del document publicat a: https://doi.org/10.1080/14737167.2017.1345628

Expert Review of Pharmacoeconomics & Outcomes Research, 2017, vol. 17, num. 6, p. 587-595

https://doi.org/10.1080/14737167.2017.1345628

Recommended citation

This citation was generated automatically.

Rights

(c) Informa Healthcare, 2017

This item appears in the following Collection(s)